NCT03994705View on ClinicalTrials.gov

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

May 27, 2021

Study Completion Date

June 11, 2021

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Descartes-11

CAR T-Cells

DRUG

Fludarabine

Pre-conditioning chemotherapy

DRUG

Cyclophosphamide

Pre-conditioning therapy

Trial Locations (2)

20817

Center for Cancer and Blood Disorders, Bethesda

53226

Medical College of Wisconsin, Madison

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Cartesian Therapeutics

INDUSTRY

NCT03994705 - Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter